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Abstract 
Coccidiosis, caused by Eimeria species parasites, has long been recognised as an economically significant disease of 
chickens. As the global chicken population continues to grow, and its contribution to food security intensifies, it is 
increasingly important to assess the impact of diseases that compromise chicken productivity and welfare. In 1999, 
Williams published one of the most comprehensive estimates for the cost of coccidiosis in chickens, featuring a com-
partmentalised model for the costs of prophylaxis, treatment and losses, indicating a total cost in excess of £38 million 
in the United Kingdom (UK) in 1995. In the 25 years since this analysis the global chicken population has doubled and 
systems of chicken meat and egg production have advanced through improved nutrition, husbandry and selective 
breeding of chickens, and wider use of anticoccidial vaccines. Using data from industry representatives including 
veterinarians, farmers, production and health experts, we have updated the Williams model and estimate that coccidi-
osis in chickens cost the UK £99.2 million in 2016 (range £73.0–£125.5 million). Applying the model to data from Brazil, 
Egypt, Guatemala, India, New Zealand, Nigeria and the United States resulted in estimates that, when extrapolated by 
geographical region, indicate a global cost of ~ £10.4 billion at 2016 prices (£7.7–£13.0 billion), equivalent to £0.16/
chicken produced. Understanding the economic costs of livestock diseases can be advantageous, providing baselines 
to evaluate the impact of different husbandry systems and interventions. The updated cost of coccidiosis in chickens 
will inform debates on the value of chemoprophylaxis and development of novel anticoccidial vaccines.
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Introduction
Eimeria are protozoan parasites that can cause the 
enteric disease coccidiosis in all major livestock species. 
The consequences of infection include malabsorption, 
enteritis and, in severe cases for some Eimeria species, 
mortality, compromising economic productivity and 
animal welfare [1]. Chickens are the most economically 
important hosts; more than 68 billion were farmed in 
2018, representing a third of all meat produced globally 
in addition to 1.38 trillion eggs for human consumption 
[2]. Chicken production is expected to increase further in 
the next decade [3], highlighting the importance of path-
ogens that affect poultry to food security and the global 
agro-economy. Avian coccidiosis has previously been 
ranked in the top three diseases of poultry in the United 
Kingdom (UK) based on economic significance [4], and 
in the top ten veterinary diseases based on impact on the 
poor in South Asia [5]. In a 2019 survey of broiler veteri-
narians in the United States (US), coccidiosis (specifically 
Eimeria maxima) was ranked as the top disease-related 
issue in the opinion of the respondents [6]. A similar sur-
vey of the US Association of Veterinarians in Egg Produc-
tion (AVEP) indicated that coccidiosis was considered 
the most important disease or condition in replacement 
Open Access
*Correspondence:  dblake@rvc.ac.uk
1 Pathobiology and Population Sciences, Royal Veterinary College, 
Hawkshead Lane, North Mymms AL9 7TA, UK
Full list of author information is available at the end of the article
Page 2 of 14Blake et al. Vet Res          (2020) 51:115 
layers reared cage-free, and the second most important 
in those reared in cages [6].
Several attempts have been made to quantify the con-
sequences of coccidiosis in chickens. Eimeria lifecycles 
have been modelled for several parasite species, assess-
ing rates of replication and/or associated pathology 
[7–12]. The financial cost has been estimated for coun-
tries including Ethiopia, India, Romania and the UK [4, 
13–15], with a model published by Williams being most 
comprehensive and most widely referenced [16]. In the 
latter study, the annual cost of coccidiosis in chickens 
was estimated to exceed £38 m in the UK at 1995 prices. 
In the intervening period the UK chicken population has 
increased by 56% (1995–2018), with far larger expansions 
experienced in some other countries including Brazil, 
China and India, such that global chicken production 
is now double that of 25 years ago [2]. During this time, 
the Williams 1995 figure of £38 m has been extrapolated 
to provide estimates of the global cost of coccidiosis in 
chickens beginning at US$0.8 billion in 2002 [17], grow-
ing to US$2.4 billion in 2005 and US$3 billion in 2006 [1, 
18], all using the original figures from 1995. In the same 
period the value of the UK £ sterling (GBP) has changed 
such that £1 in 1995 was equivalent to £1.94 in 2019 [19]. 
No further update has been published for the cost of 
coccidiosis in chickens and the calculation has not been 
repeated.
Poultry production has undergone considerable 
development over the last 25  years. Broiler growth 
rates have increased, feed conversion ratios (FCR) 
fallen and average days to market reduced in intensive 
systems [20]. Similarly, egg production has changed 
including longer, more productive laying cycles [21]. 
Poultry housing and management systems for inten-
sively reared poultry have also evolved to improve 
health, welfare and productivity. Approaches to con-
trol of coccidiosis have also changed. In the Williams 
model description of 1995, only broiler breeders were 
assumed to receive anticoccidial vaccination [16], 
whereas vaccination using formulations of live wild-
type (non-attenuated) or attenuated vaccines is now the 
dominant form of anticoccidial prophylaxis for layer 
replacement, layer and broiler breeding stocks in much 
of the World [22]. Vaccination is not yet so common 
in broiler production, although public and legislative 
pressures are encouraging the search for cost-effective 
alternatives to anticoccidial drugs, especially in coun-
tries such as the US, where (unlike the EU) ionophores 
are regulated as antibiotics. In response, 35–40% of US 
broiler companies have adopted annual cycles where 
two out of every six flocks receive anticoccidial vacci-
nation instead of drugs [23]. More recently, it has been 
reported that more than 50% of US broilers are now 
raised antibiotic-free, indicating the absence of antico-
ccidial chemoprophylaxis [6]. In addition to vaccina-
tion as a replacement for chemoprophylaxis, bioshuttle 
programmes using vaccination with a wild-type (non-
attenuated) product followed by an anticoccidial drug 
is increasingly popular in countries such as the US.
In this paper we describe the application of the Wil-
liams compartmentalised model to calculate the cost 
of coccidiosis in chickens using data collected in 2016 
from countries representing six different continents, 
including updates to address recent changes in poultry 
husbandry and marketing. Understanding of the eco-
nomic cost, or burden, of livestock diseases has evolved 
since the original publication [16, 24], recognising the 
contribution of indirect costs such as infrastructure 
and services as well as direct costs of control, mortal-
ity and morbidity. Thus, using the Williams model we 
have estimated the nominal financial cost of coccidiosis 
in chickens in 2016.
Materials and methods
Data collection
A questionnaire was prepared to capture data required 
to complete the ‘compartmentalised model for the esti-
mation of the cost of coccidiosis’ described previously by 
Williams [16], including details of feed, drug and vaccine 
costs, health and performance parameters. The ques-
tionnaire was approved by the Social Science Research 
Ethical Review Board (SSRERB) of the Royal Veterinary 
College and assigned the reference URN SR2017-1248. 
Between three and ten industry representatives includ-
ing veterinarians, farmers, integrators, poultry produc-
tion and poultry health experts were surveyed in each 
of Brazil, Egypt, Guatemala, India, New Zealand, Nige-
ria, the United Kingdom (UK, including Great Britain & 
Northern Ireland) and the United States of America (US) 
between 2016 and 2017. Respondents were anonymised 
at the time of data collection. In the UK additional data 
were collected, anonymised and amalgamated by the 
British Poultry Council (BPC), producing a dataset that 
was representative of British poultry producers and inte-
grators. Where a range of figures was recorded, the mid-
point was calculated. International poultry production 
figures were accessed using FAOSTAT (http://www.fao.
org/faost at/) [2], recording figures for 2016 to align with 
data collected from poultry industry representatives. 
FAOSTAT was originally accessed in 2018, but figures 
were subsequently updated by FAO and revised here as 
of May 19th, 2020. Additional details were accessed from 
Eurostat [25], accessed July 27th, 2020, and from broiler 
and layer management guides using the editions that 
were valid in 2016–2017, as referenced where relevant.
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Data analysis
The method developed by Williams [16] was adopted, 
including a series of 12 compartmentalised components 
covering costs related to chick purchase and rearing, 
performance, anticoccidial prophylaxis and therapy in 
broiler, layer and breeder chickens (Table  1). Equations 
used without modification are summarised, with sup-
porting data presented for all modifications. Figures used 
in analysis were updated from data recorded in the UK 
alone in 1995 to Brazil, Egypt, Guatemala, India, New 
Zealand, Nigeria, the UK and the US in 2016–2017. The 
countries included were selected to represent major 
poultry producing regions in South America, North 
Africa, Central America, Asia, Oceania, sub-Saharan 
Africa, Europe and North America, respectively.
Prices, international currency and quantity calculations
The analysis used nominal prices from 2016. The cur-
rency exchange rates used in this study were set using 
Google Currency Converter on November  13th, 2016. 
Rates against one (1) UK £ (sterling) were 0.22 Brazilian 
real, 0.719 Egyptian pounds, 0.012 Indian rupees, 0.48 
New Zealand dollars, 0.0021 Nigeria naira, and 0.719 US 
dollars (also used in Guatemala). US tons were converted 
to metric tonnes where necessary using the conversion 
factor 0.907. Calculated costs are presented in millions to 
a maximum of five significant figures to assist clarity.
Results
The cost of anticoccidial prophylaxis for commercial broiler 
chickens
Figures for annual production of broiler chickens can 
be accessed by country or region using FAOSTAT, pre-
sented as tonnes of dressed meat (search criteria: Pro-
duction/Livestock primary/Region/production quantity/
meat, chicken) or number slaughtered for meat (search 
criteria: Production/Livestock primary/Region/Produc-
ing animals slaughtered/meat, chicken), recognising 
that both will include a small proportion of non-broiler 
derived meat (e.g. spent hens) (Table  2). Consideration 
of the Cobb and Aviagen broiler management manuals 
suggested that 74.3% of a broiler carcass can be used for 
meat [26, 27], although the UK industry view was that 
71% was more realistic, a marginal increase on the figure 
presented previously [16]. Thus, figures for dressed meat 
produced can be used to estimate total liveweight with 
a meat yield factor of 1.408 (Eqs.  1 and 2). For the UK, 
and other countries in the EU, accurate data regarding 
total liveweight can be accessed directly with no need for 
these calculations using Eurostat [25], indicating produc-
tion of 1.79 million tonnes liveweight in the UK in 2016 
(Table 2).
Calculating the cost of anticoccidial prophylaxis using 
the Williams model for 1995 assumed that all broiler 
chickens received ionophore or non-ionophore (chemi-
cal) drugs [16]. By 2016, the situation was more com-
plex. While the majority of broiler chickens continued 
to receive anticoccidial drugs in the UK, up to 3% of 
broilers may have been reared drug-free under organic 
or other systems [28]. The use of live anticoccidial vac-
cines in chicken production has increased significantly 
since 1995. Anticoccidial vaccination remains uncom-
mon in UK broiler production, but 35–40% of US 
broiler producers used anticoccidial vaccines instead of 
(1)Meat yield factor = 100/% carcass used
(2)
Tonnes liveweight = Tonnes dressed meat
×Meat yield factor.
Table 1 Summary of compartments for estimation of the cost of coccidiosis and modifications undertaken here
Cost compartment (Williams [16]) Cost type Modified Modification
1. Prophylactic control for broilers Control Yes Cost of vaccine,  % broilers vaccinated
2. Vaccinating broiler breeders Control No –
3. Therapeutic treatment for broilers against coccidiosis Control No –
4. Therapeutic treatment for broiler breeders against coccidiosis Control No –
5. Broiler mortality due to coccidiosis Mortality No –
6. Reduced broiler weight due to coccidiosis Morbidity No –
7. Increased FCR Morbidity No –
8. Reduced egg production by broiler breeders Morbidity Yes Hatchability
9. Prophylaxis during rearing of replacement layers Control Yes Cost of vaccine, % replacement layers vaccinated
10. Prophylaxis for layer breeders Control Yes Cost of vaccine, % layer breeders vaccinated
11. Therapeutic treatment of layer replacements during rearing Control No –
12. Therapeutic treatment of layer breeders against coccidiosis Control No –
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chemoprophylaxis for at least two flocks per year by 2014 
[23]. Here, for the UK calculation we assume that up to 
3% of broiler chickens were vaccinated, and 97% of broil-
ers received conventional chemoprophylaxis.
Anticoccidial prophylaxis for chickens using chemi-
cal or ionophore drugs is usually administered via the 
feed. Consideration of the feed conversion ratio (FCR) 
achieved during chicken production can be used to esti-
mate total feed consumption. In the UK, our survey and 
the broiler management manuals suggested average FCR 
to have been 1.6 in 2016 [26, 27], although variation in 
efficiencies of production would be expected to change 
FCR, suggesting that the average may vary between pro-
ducers. Thus, if 1.79 million tonnes liveweight chicken 
were produced in the UK in 2016, assuming an FCR of 
1.6, the total quantity of chicken feed consumed would 
have been at least 2.87 million tonnes (Eq. 3).
(3)
Feed consumption = Tonnes liveweight× FCR.
Referring to the questionnaire, in the UK it is com-
mon practice to add an additional 10% whole wheat 
to the formulated ration, although the precise figure is 
likely to vary as the price of wheat fluctuates. Thus, for-
mulated feed represented ~ 90% of the chicken feed con-
sumed, equivalent to 2.58 million tonnes in 2016. Ross 
308, followed by Cobb500 broiler chickens were the most 
popular lines used in the UK in 2016 so the Aviagen and 
Cobb broiler nutrition and performance supplements 
were considered for feed consumption parameters [26, 
29]. The Aviagen figures indicate that ~ 6.2% of total feed 
would have been consumed as starter diet over the first 
10 days for chicks on a 42 day programme, rising to 8.9% 
on a 35 day programme [26]. Here, we have assumed an 
intermediate 39  day programme, indicating that 7.2% 
of the 2.58 million tonnes formulated feed would have 
been consumed as starter diet (Table  2 and as above). 
While practices vary considerably between produc-
ers, assuming that a starter feed containing a chemical 
(i.e. non-ionophore), or more commonly a combination 
Table 2 Values used to calculate the cost of anticoccidial prophylaxis in broiler and broiler breeder chickens
Data collected from major poultry producing countries selected to represent South, Central and North America (Brazil, Guatemala, USA), North Africa (Egypt), sub-
Saharan Africa (Nigeria), Asia (India), Europe (UK) and Oceania (New Zealand). Rows shown in italics represent new data related to anticoccidial vaccine use that were 
not included (ni) in the original model. aFigures from the UK in 1995 used in the original study published by Williams [16]. bFigures downloaded from FAOSTAT for 
the year 2016 (2020). cCost shown for 75% of actual period to account for average withdrawal period. dFigure downloaded from Eurostat for the year 2016 (2020), 
representing total liveweight, not dressed meat. Thus, the meat yield factor was not required (nr).
UK-1995a Brazil Egypt Guatemala India New Zealand Nigeria UK USA
1. Cost of broiler prophylaxis/vaccination
 Tonnes dressed meat (millions)b 1.02 13.23 1.01 0.23 3.31 0.21 0.20 1.79d 18.71
 % Carcass used 70.2 71.0 71.0 71.0 71.0 71.0 71.0 nr 71.0
 FCR 1.98 1.72 1.6 1.56 1.65 1.47 1.7 1.6 1.75
 % Formulated feed (i.e. not wheat/cereal) 95 85 85 85 80 100 80 90 86
 % Starter 25 7.2 7.2 7.2 7.2 7.2 7.2 7.2 7.2
 % Grower 55 31.8 31.8 31.8 31.8 31.8 31.8 31.8 31.8
 % Finisher (inc. drug withdrawal) 20 61.0 61.0 61.0 61.0 61.0 61.0 61.0 61.0
 Cost chemical/combination drug per tonne food £2.74 £6.20 £0.72 £2.18 £0.72 £7.00 £7.35 £5.50 £5.95
 Cost ionophore drug per tonne food £2.97 £3.20 £2.41 £1.31 £1.44 £5.00 £3.15 £3.50 £2.44
 % BROILERS reared on drugs ni 100 100 100 100 100 100 97 88
 Cost of in-feed drugs in starter diet (millions) £1.88 £12.27 £0.10 £0.07 £0.32 £0.22 £0.21 £0.99 £14.90
 Cost of in-feed drugs in grower diet (millions) £4.48 £53.73 £1.48 £0.30 £1.41 £0.97 £0.91 £4.37 £65.83
 Cost of in-feed drugs in finisher diet (millions)c ni £39.90 £2.13 £0.26 £4.05 £1.00 £0.56 £4.13 £44.12
 Vaccine (broiler) pence per dose ni 1.3 1.15 0.49 3.0 1.54 4.2 3.0 0.49
 % Broilers reared with vaccine ni 0 0 0 0 0 0 3 12
 Cost of vaccination (millions) ni £0.00 £0.00 £0.00 £0.00 £0.00 £0.00 £0.94 £5.23
 Number slaughtered per year (millions)b 624.8 5860.3 897.1 142.6 2411.6 110.0 202.8 1050.0 8908.9
 Mean finishing weight broiler (Kg) 2.33 2.7 2 1.9 2.4 2.6 2.3 2.19 2.72
 Total cost of broiler prophylaxis £6.36 £105.8 £3.70 £0.63 £5.78 £2.19 £1.67 £10.44 £130.1
2. Cost of vaccinating broiler breeders
 % Broiler breeders in population 1.15 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77
 Vaccine (breeder) pence per dose 8 1.3 3 0.49 3 9.6 4.2 8 0.49
 Total cost of broiler breeder prophylaxis (millions) £0.57 £0.59 £0.21 £0.005 £0.56 £0.08 £0.06 £0.65 £0.33
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chemical + ionophore drug, was used at an average cost 
of £5.50 drug per tonne supplemented feed, the total cost 
of supplementation would have been £0.99 million for 
broilers on an intermediate 39  day programme in 2016 
(Table  2, range £0.85-£1.22 million for 35 to 42  days). 
Between 27.3% and 39.0% of feed is consumed as grower 
diets from days 11 to 22 on 42 and 35  day broiler pro-
grammes, respectively, although many producers include 
additional switches during these periods. Ionophores are 
the most common anticoccidial drugs used in broiler 
production, representing 72.3% by weight of anticoccidial 
drugs sold in the UK in 2013, the last year that the Veteri-
nary Medicines Directorate reported on ionophore use 
[30]. Assuming that ionophore anticoccidial drugs were 
used in combination products for the first grower phase 
on a 39  day programme, the total cost of supplementa-
tion would have been £4.37 million in 2016 based upon 
31.8% of total feed consumed (Table 2; range £3.76–£5.37 
million). The majority of feed is consumed in the finisher 
phase, from day 23 onwards, representing between 66.5% 
and 52.1% of formulated feed on 42 and 35  day pro-
grammes, respectively (61.0% for 39  days). Ionophores 
are commonly fed alone during this period at an average 
cost of £3.50 per tonne supplemented feed. Withdrawal 
periods vary from 0 to 5  days, depending on the prod-
uct used, and were estimated to represent 25% of the fin-
isher phase without chemoprophylaxis, indicating a total 
cost of supplementation of £4.13 million in 2016 (range 
£3.53–£4.50 million). Thus, the total estimated cost of 
anticoccidial-supplementation in feed was £9.50 million 
for those broilers that received chemoprophylaxis in 2016 
(range £9.11–£10.12 million). Figures from FAOSTAT 
report that 1.05 billion chickens were reared for meat 
in the UK in 2016 (search criteria: Production/Live-
stock primary/Region/Producing animals slaughtered/
meat, chicken). Assuming that 97% received anticoccidial 
chemoprophylaxis, the cost for each UK broiler chicken 
treated would have been £0.01 in 2016.
The cost of anticoccidial vaccination for broiler chick-
ens is difficult to quantify, but based on our survey is 
approximately £0.03 per dose in the UK where live atten-
uated vaccines are licensed for use (Table 2). If 3% of the 
broiler chickens reared in 2016 were vaccinated, rep-
resenting 31.5 million doses, the cost would have been 
£945,000. Thus, the total financial cost of prophylaxis for 
coccidiosis (anticoccidial drugs and vaccines) in the UK 
broiler sector is estimated to have been £10.44 million in 
2016. Using the same equations populated with data col-
lected from surveys in Brazil, Egypt, Guatemala, India, 
New Zealand, Nigeria and the US suggested that the 
annual costs of broiler prophylaxis using drugs or vac-
cines would have been £105.8, £3.70, £0.63, £5.78, £2.19, 
£1.67 and £130.1 million, respectively (Table 2).
The cost of anticoccidial vaccination for broiler breeder 
chickens
As in 1995, broiler breeders are routinely vaccinated 
in the UK and much of the World against coccidiosis. 
In 1995 the percentage of broiler breeders used to pro-
duce commercial broiler progeny was estimated to have 
been at least 1.15% [16]. In 2016 this figure had dropped 
to 0.77%, equivalent to 130 chicks produced per broiler 
breeder hen, suggesting that 8.08 million breeding chick-
ens would have been required to produce the 1.05 billion 
broilers reported from the UK in 2016. The average cost 
of anticoccidial vaccination per broiler breeder in the 
UK in 2016 was £0.08, unchanged from 1995, suggesting 
a total annual cost of £0.65 million (Table 2). Equivalent 
figures for Brazil, Egypt, Guatemala, India, New Zealand, 
Nigeria and the US would have been £0.59, £0.21, £0.005, 
£0.56, £0.08, £0.06 and £0.335 million, respectively, tak-
ing into account the variable costs per dose of the live 
wild-type or attenuated vaccines licensed for use in some 
of these countries. Vaccine used in Guatemala was pro-
vided from the US market, commonly delivered to chicks 
produced in the US and shipped to Guatemala.
The cost of anticoccidial therapy for broilers and broiler 
breeders
The true occurrence of coccidiosis in broiler and broiler 
breeder stock is often poorly documented, representing 
commercially sensitive information. In the UK, the con-
sensus opinion was that the occurrence of disease out-
breaks was < 5% across all flocks, where assessment of 
‘occurrence’ is usually based on gross pathology. Labora-
tory confirmation is less common. Here, we have used fig-
ures of 3% for broiler flocks, and 2% for broiler breeders 
(Table  3). The cost of therapeutic treatment per chicken 
was estimated to be £0.02 for broiler and broiler breeders. 
When broiler and broiler breeder chickens are treated for 
coccidiosis, therapy is administered to the entire house/
pen, suggesting that 31.5 million broilers and 161,538 
broiler breeders received treatment for coccidiosis in the 
UK in 2016 (Eq. 4, Table 3). Thus, the total cost of treat-
ment for coccidiosis in the UK in 2016 was estimated to 
be £0.63 million for broilers, and £0.003 million for broiler 
breeders, although the true figures are likely to vary 
according to the actual occurrence of coccidiosis.
Application of the same equation to costs in Brazil, 
Egypt, Guatemala, India, New Zealand, Nigeria and the 
US revealed considerable variation, underpinned by nota-
bly different estimates for the occurrence of coccidiosis 
(4)
Cost of therapy = Number of chickens
× % Occurrence of coccidiosis × Cost of treatment.
Page 6 of 14Blake et al. Vet Res          (2020) 51:115 
from 5% to 80% for broilers, and 2% to 80% for broiler 
breeders (Table 3).
The cost of broiler mortality caused by coccidiosis
Our survey suggested that approximately 2% of UK broil-
ers would be expected to die or (more commonly) be 
culled in a house affected by coccidiosis (Table 4). Thus, 
if 31.5 million broilers were in houses affected by coccidi-
osis, mortality would have been 630,000 (Eq. 5). Note, the 
figure does not include losses due to subsequent mortal-
ity caused by other opportunistic pathogens.
Losses attributed to mortality were divided in the Wil-
liams model into the chicken value, including cost of pur-
chase (Eq.  6), and the revenue that had been lost when 
chickens were not sold minus the rearing costs that were 
saved due to premature mortality (Eq.  7) [16]. In total 
630,000 broilers were estimated to have died due to coc-
cidiosis in the UK in 2016 (as above). In the model, chick 
value was calculated at an average time point of 3 weeks 
of age, representing the beginning of the period when 
mortality is most likely to occur [31]. From our survey, 
each individual broiler would be worth on average £0.80 
at 3 weeks of age, indicating a total cost of £0.50 million 
(Eq. 6). The average liveweight for a commercial broiler 
in the UK at the time of slaughter in 2016 was 2.191 kg 
[27]. From our survey, an average of £0.80 was paid per 
Kg at the time of slaughter, indicating a loss of £1.75 per 
individual, balanced by a reduction in rearing costs of 
£1.12 per chicken lost, resulting in a net loss of £0.63 per 
chicken or £0.40 million in total (Eq.  7). Thus, the total 
cost of broiler mortality in the UK in 2016 was £0.90 mil-
lion. The equivalent costs for Brazil, Egypt, Guatemala, 
(5)
Mortality due to coccidiosis
= Number chickens affected by coccidiosis
× %Mortality.
India, New Zealand, Nigeria and the US would have been 
£78.52, £27.96, £0.96, £35.92, £1.14, £17.73 and £54.45 
million, respectively (Table 4).
Assuming a lower level of mortality in broiler breeder 
flocks given that most will have been vaccinated, the 
number of broiler breeders lost due to coccidiosis per 
annum would have been relatively small. The cost of 
broiler breeder loss was not calculated in the original 
Williams model for this reason, and because the actual 
cost of breeding stock is very difficult to define.
The cost of morbidity: reduced broiler weight gain due 
to coccidiosis
Eimeria are ubiquitous and it is likely that most broiler 
chickens are exposed to one or more Eimeria species dur-
ing their lives [32]. While severe coccidiosis can result in 
mortality, morbidity is far more common with both malab-
sorptive and haemorrhagic enteric disease compromising 
nutrient absorption and body weight gain [33]. In the origi-
nal model the average effect of coccidiosis was estimated 
to reduce final bodyweight by 0.1  kg when compared to 
an unexposed equivalent, although 0.05 kg was used as a 
conservative estimate [16]. Consideration of more recent 
studies with malabsorptive Eimeria species such as E. 
acervulina and E. maxima suggest a greater impact, with 
reductions in excess of 0.1 kg [33, 34], although the conse-
quences of infection with less pathogenic species such as E. 
mitis and E. praecox are less clear. In line with these data, 
(6)
Value of chickens lost due to coccidiosis
= Chicken mortality
× Estimated value at 3 weeks
(7)
Net loss =[(Number dead× Av. liveweight at slaughter)
× £ per Kg at slaughter]−
(
Number dead
× Cost of rearing to final weight from 3 weeks
)
.
Table 3 Values used to calculate the cost of anticoccidial therapy in broiler and broiler breeder chickens
Data collected from major poultry producing countries selected to represent South, Central and North America (Brazil, Guatemala, USA), North Africa (Egypt), sub-
Saharan Africa (Nigeria), Asia (India), Europe (UK) and Oceania (New Zealand). aFigures from the UK in 1995 used in the original study published by Williams [16]. bThe 
cost of treatment in New Zealand was set artificially low since it is very rare for broilers to be treated for coccidiosis due to drug residue regulations.
UK-1995a Brazil Egypt Guatemala India New Zealand Nigeria UK USA
3. Cost of broiler therapy against coccidiosis
 % Flocks affected by coccidiosis 2 8 35 80 5 80 30 3 10
 Pence treatment per bird 3.18 3.10 0.43 7.19 1.20 0.2b 5.25 2.00 2.88
Total cost of broiler therapy (millions) £0.40 £14.53 £1.35 £8.21 £1.45 £0.18 £3.19 £0.63 £25.64
4. Cost of broiler breeder therapy against coccidiosis
 % Flocks affected by coccidiosis 1 8 25 80 2 80 50 2 10
 Pence treatment per bird 2.03 2.90 4.32 7.19 1.20 19.20 4.73 2.00 10.79
 Total cost of broiler breeder therapy (millions) £0.001 £0.10 £0.07 £0.06 £0.004 £0.13 £0.04 £0.003 £0.74
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and recognition of increased growth rate in modern broiler 
chickens and hence greater likely impact of infection, 
our conservative estimate of final reduction in live body-
weight as a consequence of Eimeria infection was raised 
to 0.07 kg (Table 4). Thus, with 1.05 billion broiler chick-
ens produced in the UK in 2016, the predicted total loss of 
body weight caused by Eimeria infection would have been 
73,500,000 kg. Given the value of £0.80 per Kg bodyweight 
at slaughter (as above), the loss would have equated to a 
total of £58.80 million (Eq. 8, Table 4). Changing the esti-
mated reduction in live bodyweight by ± 0.02 kg resulted in 
a 28.6% increase/decrease in total cost (between £42.00 and 
£75.60 million). The equivalent costs of a 0.07 kg reduction 
in broiler body weight gain for Brazil, Egypt, Guatemala, 
India, New Zealand, Nigeria and the US would have been 
£512.78, £54.22, £5.17, £334.26, £7.39, £29.82 and £687.43 
million, respectively.
The cost of morbidity: higher feed conversion ratios (FCR) 
due to coccidiosis
In addition to lower final bodyweight, reduced nutri-
ent absorption as a consequence of coccidiosis will also 
be reflected by a higher feed conversion ratio (FCR). 
A higher FCR illustrates the requirement for greater 
feed intake to achieve the same bodyweight gain due to 
inefficiencies in diet utilisation and in additional nutri-
ent partition to repair damaged enteric tissues and 
the birds immune response. The influence of Eimeria 
infection on FCR is difficult to define. A wide range of 
variation has been reported, often following significant 
(8)
Cost of reduced weight gain =
(
Number of chickens




× £ per Kg at slaughter.
Table 4 Values used to calculate the performance costs of coccidiosis in broiler and broiler breeder chickens
Data collected from major poultry producing countries selected to represent South, Central and North America (Brazil, Guatemala, USA), North Africa (Egypt), sub-
Saharan Africa (Nigeria), Asia (India), Europe (UK) and Oceania (New Zealand). Rows shown in italics represent new data related to hatchability that were not included 
(ni) in the original model. aFigures from the UK in 1995 used in the original study published by Williams [16]. bFigures taken from the Cobb broiler management guide 
(Cobb-Vantress [29]). cFigures not available; replaced with those from Williams [16].
UK-1995a Brazil Egypt Guatemala India New Zealand Nigeria UK USA
5. Cost of broiler mortality due to coccidiosis
 % Mortality due to coccidiosis 0.5 5.5 5.5 1.0 7.5 1.5 7.5 2.0 2.0
 Value, including chick costs, at 3 weeks £0.52 £0.62 £0.90 £0.65 £0.72 £0.77 £0.74 £0.80 £0.42
 Av liveweight at slaughter (Kg) 2.33 2.7 2.0 1.9 2.4 2.6 2.3 2.19 2.72
 Av slaughter price/Kg £0.57 £1.25 £0.86 £0.52 £1.98 £0.96 £2.10 £0.80 £1.10
 Cost of rearing bird to final weight (no chick 
costs)
£1.02 £0.95 £1.01 £0.79 £1.50 £0.62 £1.68 £1.12b £0.36
 Total cost of broiler mortality (millions) £0.05 £78.52 £27.96 £0.96 £35.92 £1.14 £17.73 £0.90 £54.45
6. Cost of reduced weight due to coccidiosis
 Average broiler weight loss due to coccidiosis 
(Kg)c
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
 Conservative prediction of weight loss (Kg) 0.05 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07
 Value loss per Kg (selling price per Kg) £0.57 £1.25 £0.86 £0.52 £1.98 £0.96 £2.10 £0.80 £1.10
 Total cost of reduced weight gain (millions) £17.91 £512.8 £54.22 £5.17 £334.3 £7.39 £29.82 £58.80 £687.4
7. Cost of increased FCR
 Increased FCR as a consequence of  coccidiosisc 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
 Conservative estimate FCR  increasec 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
 Mean formulated feed price per tonne £180.61 £280.00 £251.80 £393.00 £318.00 £297.60 £315.00 £275.00 £218.13
 Mean wheat (or other cereal) price per tonne £113.50 £140.00 £160.00 £178.00 £150.00 £192.00 £150.00 £160.00 £145.00
 % formulated feed (i.e. not wheat/cereal) 95 85 85 85 80 100 80 90 86
 Total cost of increased FCR (millions) £13.15 £241.4 £16.88 £5.95 £66.26 £4.42 £4.03 £23.60 £273.9
8. Cost reduced egg production by broiler breeders
 % Broiler breeders that were parent hens 72.4 90.9 90.9 90.9 90.9 90.9 90.9 90.9 90.9
 % Broiler egg hatchability ni 85 85 85 85 85 85 85 85
 Cost one day old broiler chick £0.23 £0.30 £0.22 £0.42 £0.34 £0.34 £0.38 £0.33 £0.23
 Cost of lower broiler breeder egg production 
(millions)
£0.01 £0.84 £0.29 £0.28 £0.10 £0.18 £0.23 £0.04 £1.22
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parasite challenge that might exceed common levels of 
challenge in the field. In the original model, Williams 
considered the effect of Eimeria infection on FCR to be 
an increase of 0.1, using 0.05 as a conservative meas-
ure. We have used the same figures here (Table  4). 
From our survey, broiler diets commonly include 10% 
wheat at an average cost of £160 per tonne in the UK 
in 2016, although wheat prices can vary significantly 
resulting in notable variation over time. Formulated 
feed, commonly representing 90% of the total diet, 
cost on average £275 per tonne (Table  4). Combined, 
the mean feed price can be calculated using Eq.  9 to 
be £263.50 per tonne in the UK in 2016. Thus, using 
the figures for broiler liveweight produced per annum 
described above, a predicted FCR increase of 0.05, and 
a mean feed price of £263.50 per tonne, the total cost 
of increased FCR due to coccidiosis was £23.60 (Eq. 10). 
Changing the estimated increase in FCR by ± 0.02 
resulted in a 40.0% increase/decrease in total cost 
(between £14.16 and £33.03 million). Feed costs and 
ratios for formulated: non-formulated feed use varied 
between countries (Table 4), resulting in total costs of 
£241.40, £16.88, £5.95, £66.26, £4.42, £4.03 and £273.89 
million for Brazil, Egypt, Guatemala, India, New Zea-
land, Nigeria and the US, respectively, when using an 
increased FCR of 0.05.
The cost of morbidity: lower broiler breeder egg 
production
In the UK in 2016, we already estimated 161,538 broiler 
breeder chickens would have been affected by coccidiosis. 
A sex ratio of one male per ten females has been described 
for modern broiler breeder chickens [35], suggesting that 
146,853 broiler breeder hens were used. The effect of 
Eimeria infection on egg production is not clear. The Wil-
liams model took a conservative approach, suggesting the 
loss of one egg per hen, per year. An additional param-
eter not considered in the original model is hatchability. 
While one egg may have been lost per hen, per year, only 
85% might have been expected to yield a chick [36]. From 
(9)
Mean feed price = (Mean price of formulated feed
×% formulated feed used)
+ (Mean price of non− formulated feed (cereal)×
% non− formulated feed used)
(10)







× Predicted FCR increase
)





our survey, the average cost for a day old broiler chick in 
the UK was £0.33, suggesting a total loss of £0.04 million. 
The equivalent costs for Brazil, Egypt, Guatemala, India, 
New Zealand, Nigeria and the US were £0.84, £0.29, £0.28, 
£0.10, £0.18, £0.23 and £1.22 million, respectively (Table 4), 
with the differences reflecting different levels of coccidiosis 
reported in broiler breeder flocks from different countries.
The cost of anticoccidial prophylaxis for commercial layer 
chicken replacements
The number of layers reared in the UK each year can be 
estimated using FAOSTAT (search criteria: Production/
Livestock primary/Region/Producing animals/slaugh-
tered/eggs, hen, in shell), indicating that 53,489,000 
hens were reared in total. In the Williams model, it 
was important to differentiate between replacement 
hens kept in cages or on litter, since different anticoc-
cidial prophylaxis programmes were used. However, 
comparison of management guides for chickens reared 
in enriched cages or on the floor indicate that both 
now follow step-down programmes [37, 38]. Figures 
released by the Royal Society for the Prevention of Cru-
elty to Animals (RSPCA) suggest that 48% were accom-
modated as laying stock in enriched cages, with 1% in 
barn systems and 51% free range, of which 2% were 
organic [39] (Table 5).
In the original Williams model the use of vaccination 
in anticoccidial prophylaxis for layer chickens was not 
considered, reporting 100% chemoprophylaxis [16]. By 
2016, the situation had changed significantly, with at 
least 95% of layer chickens receiving live anticoccidial 
vaccination in the UK. From our survey, the average 
cost of an anticoccidial vaccine was 8p per dose in UK 
in 2016 (Table 5). Thus, if 95% of laying hens received 
vaccines, the total cost would have been £4.06 million.
Comparison of management guides for rearing com-
mercial layer chickens in caged or alternative systems 
in UK suggested that stock reared using anticoccidial 
chemoprophylaxis usually follow step-down approaches 
divided into two or three different phases [37, 38]. Most 
commonly, ionophores were included at 100% of the 
optimal recommended rate from 0 to 6 weeks, or 0 to 3 
and 4 to 6 weeks of age, respectively, followed by a final 
phase with ionophore at the minimum registered inclu-
sion rate for 7–12  weeks [16]. The management guide 
suggests consumption of 0.40  kg, 0.71  kg and 2.22  kg 
feed during each phase of the three step system, respec-
tively [38] (Table 5). Using the cost of £3.50 per tonne 
for ionophore supplementation at 100% of the rec-
ommended rate (as described above), the total cost of 
anticoccidial chemoprophylaxis for replacement layer 
hens in UK in 2016 was £0.03 million.
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When the costs of prophylaxis for replacement layer 
chickens using drugs and vaccines are combined the 
total cost in 2016 in the UK would have been £4.09 mil-
lion. Using the figures collected from our surveys in 
Brazil, Egypt, Guatemala, India, New Zealand, Nigeria 
and the US the total cost of prophylaxis for replace-
ment layer hens was £3.87, £0.38, £0.10, £2.53, £0.34, 
£1.15 and £1.82 million, respectively, in 2016 (Table 5).
The cost of anticoccidial prophylaxis for layer breeder 
chickens
The majority of layer breeder chickens are now routinely 
vaccinated in the UK, and much of the World, to control 
coccidiosis. Assuming that the ratio of layer breeders to 
commercial layer progeny remained comparable to that 
used for 1995 (1.21%, Table  5), 647,217 layer breeder 
chickens would have been required in the UK in 2016. 
The average cost of anticoccidial vaccination per layer 
breeder in the UK in 2016 was 8p. Assuming a ratio of 
vaccination to chemoprophylaxis comparable to that 
used for replacement layers, the total annual cost of layer 
breeder prophylaxis would have been £0.05 million in the 
UK (Table  5). Equivalent figures for Brazil, Egypt, Gua-
temala, India, New Zealand, Nigeria and the US would 
have been £0.05, £0.005, £0.001, £0.11, £0.004, £0.02 and 
£0.02 million, respectively, again influenced by a far lower 
vaccine cost per dose in the US.
The cost of anticoccidial therapy for layer and layer 
breeder chickens
Based upon the figures shown above, 27,814,280 layer 
and 647,217 layer breeder chickens may have been floor-
raised in UK in 2016. If ~ 4% of flocks required treatment 
for coccidiosis at a cost of 2p per individual (Table 5), the 
total cost would have been £0.02 and £0.0005, respec-
tively (using Eq.  4). When considering costs for Brazil, 
Egypt, Guatemala, India, New Zealand, Nigeria and the 
Table 5 Values used to calculate the cost of prophylaxis and therapy in layer and layer-breeder chickens
Data collected from major poultry producing countries selected to represent South, Central and North America (Brazil, Guatemala, USA), North Africa (Egypt), sub-
Saharan Africa (Nigeria), Asia (India), Europe (UK) and Oceania (New Zealand). Rows shown in italics represent new data related to anticoccidial vaccine use that were 
not included (ni) in the original model. aFigures from the UK in 1995 used in the original study published by Williams [16]. bFigures downloaded from FAOSTAT for the 
year 2016 (2020). cFigures taken from the Hy-Line commercial layer management guide (Hy-Line, 2016a). dFigures not available; replaced with those from Williams 
[16].
UK-1995a Brazil Egypt Guatemala India New Zealand Nigeria UK USA
9. Cost prophylaxis during rearing of replacement layers
 Number layer chickens (millions)b 32.0 329.0 34.2 20.1 382.7 3.7 111.4 53.5 365.3
 % Reared in cages 60 70 65 10 80 50 10 48 50
 % Reared on litter or ground (barn, free-range) 40 30 35 90 20 50 90 52 50
 Vaccine (layer) pence per dose ni 1.3 1.15 0.49 3 9.6 4.2 8 0.49
 Feed consumed during step-down (Kg, weeks 0–3)c 0.36 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40
 Feed consumed during step-down (Kg, weeks 4–6)c 0.74 0.71 0.71 0.71 0.71 0.71 0.71 0.71 0.71
 Feed consumed during step-down (Kg, weeks 
7–12)c
2.00 2.22 2.22 2.22 2.22 2.22 2.22 2.22 2.22
 % Reared fed drugs ni 30 5 5 90 5 95 5 5
 % Reared vaccinated ni 70 95 95 10 95 5 95 95
 Total cost of layer replacement prophylaxis (millions) £0.11 £3.87 £0.38 £0.10 £2.53 £0.34 £1.15 £4.09 £1.82
10. Cost prophylaxis for layer breeders
 % Layer flock as  breedersd 1.21 1.21 1.21 1.21 1.21 1.21 1.21 1.21 1.21
 Vaccine (breeder) pence per dose ni 1.3 1.15 0.49 3 9.6 4.2 8 0.49
 % Layer breeders on drugs ni 10 0 0 50 0 90 0 0
 % Layer breeders vaccinated ni 90 100 100 50 100 10 100 100
Total cost of layer breeder prophylaxis (millions) £0.003 £0.05 £0.005 £0.001 £0.11 £0.004 £0.02 £0.05 £0.02
11. Cost of treating layer replacements during rearing
 % Flocks affected by coccidiosis 5 5 10 80 5 80 15 4 5
 Pence total cost of treatment 1.9 2.9 4.32 7.19 1.2 19.2 4.7 2.0 2.5
 Total cost of layer replacement therapy (millions) £0.01 £0.14 £0.05 £0.92 £0.05 £0.28 £0.71 £0.02 £0.23
12. Cost of treating layer breeders during rearing
 % Flocks affected by coccidiosis 5 5 10 80 5 80 15 4 5
 Pence total cost of treatment 1.9 2.9 4.32 7.19 1.2 19.2 4.7 2.0 2.5
 Total cost of layer breeder therapy (millions) £0.0004 £0.006 £0.002 £0.01 £0.003 £0.007 £0.009 £0.0005 £0.005
Page 10 of 14Blake et al. Vet Res          (2020) 51:115 
US the figures demonstrated notable variation, reflecting 
differences in the occurrence of coccidiosis and the costs 
of therapy (Table 5).
The financial cost of coccidiosis in chickens
Combined, the 12 compartments previously described in 
the Williams model have been used to estimate the cost 
of coccidiosis in the UK [16]. Repeating the analysis using 
figures for the UK updated to 2016 suggest a combined 
total nominal financial cost of £99.23 million per annum; 
a 2.6-fold increase from the last calculation in 1995.
Considerable interest exists in calculating the global 
cost of coccidiosis in chickens. Extrapolation of any sort 
is hazardous and will certainly be inaccurate, failing to 
adapt to regional variation in consumer preferences, 
markets, environments, husbandry and biosecurity. In an 
effort to reduce such inaccuracies we have also calculated 
the total cost of coccidiosis using an updated version of 
the Williams model for Brazil, Egypt, India, Guatemala, 
New Zealand, Nigeria and the US, each representing a 
different continent or distinct region, and presenting 
a range of costs between £16.34 and £1175.88 million 
(Table 6). Taking these countries as exemplars, the total 
cost of coccidiosis in chickens in 2016 per continent or 
region was shown to vary between £112.39 and £5181.97 
million (Table  6), resulting in a global estimated total 
cost of £10,362.03 in 2016. Adjusting the estimates used 
for weight gain lost during infection and FCR increase 
as a consequence of infection by ± 0.02 in each country 
resulted in between 17.3% and 26.4% variation (Table 6). 
Thus, the range for the global cost of coccidiosis was esti-
mated to fall between £7711.51 and £13,012.54 million 
per annum. Based upon the number of chickens slaugh-
tered and the total calculated cost, the average cost of 
coccidiosis per chicken produced was £0.16.
Partition of the financial cost calculated for each coun-
try into costs associated with control (drugs for prophy-
laxis, vaccines), mortality or morbidity revealed notable 
variation (Table  7). The contribution to cost attributed 
to control was greatest in Guatemala (44.6%) and low-
est in India (2.4%). Costs associated with mortality were 
proportionately highest in Nigeria (30.2%) and Egypt 
(26.2%), lowest in the UK (0.9%). The costs of morbidity 
were most important, representing more than 80% of the 
total financial cost in India, the UK and the US (Table 7).
Discussion
Understanding the financial cost of diseases that compro-
mise animal production and welfare is important, pro-
viding a baseline for comparison of husbandry systems, 
risk factors and interventions [40]. Eimeria are the most 
economically significant parasites of poultry but their 
true cost to producers remains unclear. In 1995, the cost 
of coccidiosis to UK chicken production was estimated to 
be £38.59 million, of which 98.1% was attributed to the 
Table 6 The total cost of coccidiosis calculated per country and extrapolated per region
a  Figures downloaded from FAOSTAT for the year 2016 (2020). bThe range is represented by the percentage change incurred when adjusting estimated body weight 
gain lost and FCR increased by +0.02 (higher impact) or − 0.02 (lower impact).
Region Slaughtered 
(millions)a
Example country Total cost of coccidiosis (millions £) Rangeb
(% slaughtered per region) Example country Extrapolated 
to region
N. Africa 1971.7 Egypt (45.5%) £105.13 £231.04 ±26.4%
Sub-Saharan Africa 2409.4 Nigeria (8.4%) £58.67 £696.82 ±27.3%
Asia 27 957.7 India (8.6%) £447.01 £5181.97 ±17.3%
Europe 10 831.5 UK (9.7%) £99.23 £1023.58 ±25.4%
N. America 9615.6 USA (92.7%) £1175.88 £1269.14 ±17.3%
C. America 2297.7 Guatemala (6.2%) £22.31 £359.46 ±23.8%
S. America 9094.2 Brazil (64.4%) £958.62 £1487.61 ±26.0%
Oceania 757.0 New Zealand (14.5%) £16.34 £112.39 ±21.2%
World 65 326.8 £10 362.03 ± 25.6%
Table 7 The contribution of  costs for  control, mortality 
and morbidity to the cost of coccidiosis (millions)






Brazil £125.09 (13.0) £78.52 (8.2) £755.01 (78.8)
Egypt £5.79 (5.5) £27.96 (26.6) £71.39 (67.9)
Guatemala £9.95 (44.6) £0.96 (4.3) £11.40 (51.1)
India £10.47 (2.4) £35.92 (8.0) £400.61 (89.6)
New Zealand £3.21 (19.6) £1.14 (7.0) £11.99 (73.4)
Nigeria £6.86 (11.7) £17.73 (30.2) £34.07 (58.1)
UK £15.89 (16.0) £0.90 (0.9) £82.44 (83.1)
US £158.88 (13.5) £54.45 (4.6) £962.55 (81.9)
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broiler sector. Recalculating the figure using prices from 
2016, including costs associated with vaccination, indi-
cate a financial cost of £99.23 million per annum, 95.1% 
of which derived from broiler production. The notable 
increase in cost can be explained in part by the larger 
chicken population and currency inflation, although 
costs associated with broiler prophylaxis and impacts 
on growth (reduced weight gain and increased FCR) 
were notably higher, likely amplified by the consider-
able genetic progress achieved by the primary breeding 
companies in selection for faster growing and more feed-
efficient broiler stock [20]. The increased cost of coccidi-
osis may also have been influenced by the withdrawal of 
antibiotic growth promoters (AGPs) from chicken diets. 
The impact of coccidiosis on gut integrity can be more 
severe in chickens that are not receiving AGPs as the 
damage caused by coccidiosis provides substrates for the 
replication of certain bacteria, disrupting the balance of 
the intestinal microbiome [41, 42], potentially exacerbat-
ing malabsorption and enteritis, decreasing growth rates 
and increasing FCR.
The number of chickens estimated to be affected by 
coccidiosis was also notably higher than the figures used 
by Bennett and Ijpelaar, who predicted in 2005 a range 
of costs in the UK between £10.2 and £14.2 million per 
annum [4]. The percentage of broiler chickens lost due to 
coccidiosis was notably higher in every country surveyed 
in 2016 than the UK in 1995, possibly representing an 
underestimate in the original model [16]. Costs attributed 
to coccidiosis in layer replacements in the UK remained a 
small proportion of the total (4.15% of the total cost in 
2016), but represented a 37-fold increase from 1995. The 
increase was primarily due to greater costs of prophy-
laxis, reflecting the switch from chemoprophylaxis to 
vaccination driven in part by the BEIC Lion code that 
forbids the use of in-feed anticoccidials from the age of 
12 weeks in replacement layers [43]. Additionally, the use 
of relatively expensive live attenuated anticoccidial vac-
cines in the UK that include most or all Eimeria species 
will have increased the cost further. It is worth noting 
that levels of vaccination in replacement layer stock may 
vary between countries. The increase was replicated in 
layer breeding stock.
Application of the updated model to data collected 
from surveys in Brazil, Egypt, Guatemala, India, New 
Zealand, Nigeria and the US revealed considerable vari-
ation in the costs of production, the occurrence of infec-
tion and the outcomes of disease. The occurrence of 
coccidiosis was considered to be far higher in Egypt, Gua-
temala, New Zealand and Nigeria than the other coun-
tries surveyed, directly contributing to increased costs 
for treatment and mortality. The visible consequences 
of clinical coccidiosis were lower in Brazil, India, the 
UK and the US, where costs associated with morbidity 
were proportionately higher. The balance between losses 
incurred due to coccidiosis and the costs of prevention 
may reflect country-specific access to best practice tech-
nologies and chicken lines that are best adapted to their 
environment(s). Variation in the ongoing development 
of capacity and practice in each country is likely to have 
contributed to the differences reported in mortality and 
is not directly captured in this model.
The prices of feed, and especially vaccine doses, were 
far lower in the US than any of the other countries, lim-
iting the costs of prophylaxis per layer and broiler/layer 
breeder, and the consequences of increased FCR. Coun-
tries such as the US routinely use non-attenuated antico-
ccidial vaccines with a greater productive capacity, and 
thus lower cost, than the attenuated vaccines licenced 
for use in the EU. It is worth noting that bioshuttle pro-
grammes, including use of a non-attenuated live vaccine 
followed by an anticoccidial drug, are increasingly popu-
lar in countries such as the US, incurring increased costs 
due to tandem prophylaxis and suggesting that figures for 
the US are an underestimate. The cost of coccidiosis in 
chickens in India has previously been estimated to be 1.14 
billion Indian rupees (INR) in 2003–2004 [13], equivalent 
to £17 million, based upon a historic conversion rate of 
£1: INR 67 [44]. The figure presented here is far higher, 
in part reflecting the rapid expansion of poultry produc-
tion in the region [3], but perhaps also a more compre-
hensive model. Previous figures for the other countries 
assessed were not available to be compared. Flock-level 
analyses have been reported from Ethiopia and Roma-
nia, identifying costs of 898.80–5301.80 Ethiopia Birr 
per farm, or 0.55 and 0.53 Birr per chicken in small and 
large scale farms, respectively, in Ethiopia [15], and of 
EU€3162.4 per flock in Romania in 2010 [14]. Fornace 
and colleagues assessed the impact of individual Eimeria 
species occurrence on the viability of small broiler farms 
in Ghana, Tanzania and Zambia, calculating farm gross 
economic margins and identifying reductions associated 
with more pathogenic species [45]. The impact of sub-
clinical Eimeria infection has been investigated in Nor-
way, where the authors identified a significant impact but 
did not discuss costs [46].
Figures used to define the ‘global cost’ of coccidiosis in 
chickens have been cited widely and have varied enor-
mously [1, 17, 18]. We have estimated the financial cost 
for eight key countries, across six continents, which are 
defined by a significant contribution to chicken produc-
tion in their region. Brazil and the US, selected to rep-
resent South and North America, are among the World’s 
biggest producers of poultry. Egypt and Nigeria, chosen 
to represent North and sub-Saharan Africa, lead produc-
tion within their respective regions. India is host to one 
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of the biggest expansions in poultry production in the 
World [3]. Guatemala and New Zealand were pragmatic 
selections based on availability of data. While production 
levels are far lower in the latter countries, they are rep-
resentative of their wider regions. Using data from these 
countries and the UK, representing Europe, we have esti-
mated the total financial cost of coccidiosis in chickens 
per region in an effort to reduce variation. It is important 
to note that the figures are far from comprehensive and 
doubtless miss regional variation from other countries. 
Nonetheless, extrapolating by continent or region, rather 
than from a single country, does serve to reduce gross 
variation and strengthen a tentative estimate of the global 
cost of coccidiosis in chickens. It is important to note 
that this estimate remains based on a model that relies on 
many assumptions. As such, the figure of ~ £10.36 billion, 
or £0.16 per chicken produced, can only be considered 
to be a guide. Variation of important parameters such as 
body weight gain lost in Kg and FCR (both ± 0.02) pro-
duced a range of estimates from £7.71 to £13.01 billion 
per annum. Variation in other parameters would expand 
the range further. The model does not take an entirely 
holistic view, omitting details such as costs of rent, loans 
or mortgages, overheads such as electricity and water, 
or depreciation of facilities and equipment, all of which 
may serve to increase the true economic cost. Similarly, 
the model does not include the consequences of gut dys-
biosis caused by coccidial infection. Eimeria infection 
has been shown to modify enteric bacterial population 
structures with significant variation in commensal gen-
era such as Bacteroides and Lactobacillus [41, 47]. Vari-
ation in microbiome composition has been associated 
with higher or lower FCR [48], potentially exacerbating 
the two biggest components of the cost of coccidiosis 
(reduced weight gain and increased FCR). Eimeria infec-
tion has also been associated with increased pathogen 
carriage. Concurrent E. tenella infection can increase 
intestinal Campylobacter jejuni and Salmonella enterica 
Typhimurium load [42, 49]. Most importantly, Eimeria 
co-infection is a major contributory factor to necrotic 
enteritis (NE) caused by Clostridium perfringens [50]. 
The global cost of NE has been estimated to exceed US$6 
billion [51], adding considerable extra indirect expense to 
the direct cost of coccidiosis in chickens. The influence 
of gut dysbiosis due to Eimeria infection on litter quality 
has also not been included. Wet litter resulting from dys-
biosis is a notable risk factor for pododermatitis, a lead-
ing cause of ill health, culling, condemnation and quality 
downgrades [52]. Pododermatitis is also used as a welfare 
indicator; its occurrence can result in reputational dam-
age to a producer/integrator. Practically, wet litter caused 
by dysbiosis can incur extra costs associated with addi-
tional bedding, labour and electricity for extraction fans 
and heating to remove moisture. In the future, under-
standing the broader contribution of Eimeria infection 
and coccidiosis to overall health burdens in chickens 
will underpin improved estimates of true economic cost 
beyond the absolute figures provided here. Projects such 
as the Global Burden of Animal Diseases (GBADs) aim 
to explore this topic, establishing baseline figures for 
production of livestock in the absence of pathogens and 
defining the consequences of infection [40].
The most significant addition required to update the 
Williams model to calculate the cost of coccidiosis in 
chickens related to the far wider use of live anticoc-
cidial vaccines. Anticoccidial vaccines have become the 
dominant form of anticoccidial prophylaxis in layer and 
breeding stock around much of the World [22], with bur-
geoning interest in “no antibiotics, ever” food produc-
tion expected to increase vaccine use further. It has been 
suggested that more than 40% of US broiler producers 
now use anticoccidial vaccines in at least one flock each 
year [53], supported by statistics from a leading industry 
benchmark that more than 30% of commercial broilers 
sold in the US since 2016 have received an anticoccidial 
vaccine (personal communication). Expanding the use 
of live vaccines further has been limited by production 
capacity, especially for the less productive attenuated vac-
cines used in the EU [54]. The possible future emergence 
of recombinant or vectored anticoccidial vaccines would 
require further amendments to the model and could sig-
nificantly influence the economics of chicken production.
In conclusion, the global cost of coccidiosis in chick-
ens is estimated to have been ~ £10.36 billion in 2016, 
including losses during production and costs for prophy-
laxis and treatment. As the human population contin-
ues to expand and the challenge to achieve food security 
increases [3], improving understanding and control of 
economically significant pathogens of livestock remains 
essential.
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